Canagliflozin Lawsuit: NY Claims & Legal Options

Canagliflozin is the active ingredient in Invokana, a type 2 diabetes drug made by Janssen Pharmaceuticals. Lawsuits allege it causes serious side effects including lower limb amputations, diabetic ketoacidosis (DKA), acute kidney injury, and bone fractures. Plaintiffs argue the manufacturer failed to adequately warn patients and prescribing physicians about these risks.

In New York, you may be eligible to file a product liability claim if you took canagliflozin and suffered a lower limb amputation, diabetic ketoacidosis, acute kidney injury or kidney failure, or serious bone fractures. The FDA issued a Black Box Warning in 2017 for amputation risk — later removed in 2020 after newer clinical trial data showed a lower (though still elevated) risk when patients are properly monitored — and updated its DKA warnings in 2015, strengthening the basis for failure-to-warn claims under NY law.

New York’s statute of limitations for personal injury and product liability claims is three years under CPLR §214. Under CPLR §214-c, New York's discovery rule for latent injuries from exposure to a substance (which includes ingestion of a drug), the three-year clock generally starts from when you discovered the injury, or reasonably should have discovered it — not necessarily from when you first took the medication. Calculating this deadline can still be complex, especially if it took time to connect your injury to canagliflozin specifically, so consult an attorney as soon as possible to protect your rights.

Eligible New York plaintiffs may seek compensation for medical expenses (including amputation surgery and rehabilitation), lost wages, pain and suffering, and long-term disability costs. New York does not cap compensatory damages in personal injury cases, though each case depends on individual facts and injuries. No specific outcome is guaranteed, and you should speak with an attorney to evaluate your claim.